Polypills with or without aspirin for primary prevention of cardiovascular disease

Polypills with or without aspirin for primary prevention of cardiovascular disease

Detalles Bibliográficos
Main Authors:	Mant, J, McManus, R
Formato:	Journal article
Idioma:	English
Publicado:	Elsevier 2021

Títulos similares

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
por: Virdee, S, et al.
Publicado: (2013)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease
por: Jowett, S, et al.
Publicado: (2017)

Polypill for cardiovascular disease prevention.
por: Dalton, A
Publicado: (2013)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
por: Sue Jowett, et al.
Publicado: (2017-01-01)

The Concept of the Polypill in the Prevention of Cardiovascular Disease
por: Brandon Wiley, et al.
Publicado: (2014-04-01)

Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease
por: J. Masjuan, et al.
Publicado: (2021-01-01)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Omneya A. Kandil, et al.
Publicado: (2022-04-01)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
por: Apichard Sukonthasarn, et al.
Publicado: (2021-03-01)

Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study.
por: Sheppard, J, et al.
Publicado: (2014)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
por: Lopez-Lopez JP, et al.
Publicado: (2023-09-01)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
por: Gunaratne Padma S, et al.
Publicado: (2011-01-01)

Medicinal herbs: Potential polypills in cardiovascular diseases
por: Samaneh Noroozi, et al.
Publicado: (2021-04-01)

Exercise Rehabilitation in Heart Disease: the real “polypill” for primary and secondary prevention
por: Massimo F. Piepoli
Publicado: (2005-06-01)

The polypill: the solution for prevention of coronary heart disease?
por: Hendarto Natadidjaja
Publicado: (2016-02-01)

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study.
por: Sheppard, J, et al.
Publicado: (2012)

THE ROLE OF POLYTABLETS (POLYPILL) IN THE TREATMENT OF CHRONIC CARDIOVASCULAR DISEASES
por: Николай Владимирович Абрамов, et al.
Publicado: (2024-02-01)

Role of aspirin in primary prevention of cardiovascular disease
por: Patrono, C, et al.
Publicado: (2019)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer JJ, et al.
Publicado: (2014-12-01)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Ying Xing, et al.
Publicado: (2019-07-01)

Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study
por: Ramin Ravangard, et al.
Publicado: (2024-07-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
por: Lilian Grigorian-Shamagian, et al.
Publicado: (2021-08-01)

Maybe it's time for something a little different? The extent to which current pharmacotherapy practice conforms to national guidelines for primary for cardiovascular disease prevention
por: Sheppard, J, et al.
Publicado: (2013)

The use of polypills in cardiovascular disease management: Benefits vs challenges
por: Yamaan Adil, et al.
Publicado: (2024-09-01)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
por: Reza Jahangiri, et al.
Publicado: (2022-01-01)

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
por: Hennekens, C, et al.
Publicado: (1989)

A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
por: Gautam Satheesh, et al.
Publicado: (2024-07-01)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
por: Yinong Chen, et al.
Publicado: (2021-09-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
por: Siddharth Birla, et al.
Publicado: (2023-09-01)

Which people should take aspirin for primary prevention of cardiovascular disease?
por: Lozano R, et al.
Publicado: (2015-07-01)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Sergio Coccheri
Publicado: (2017-04-01)

Aspirin for prevention of cancer and cardiovascular disease.
por: Rose, P, et al.
Publicado: (2011)

Correction: A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
por: Gautam Satheesh, et al.
Publicado: (2024-08-01)

Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a)
por: Eleni Giannopoulou, et al.
Publicado: (2024-12-01)

US population qualifying for aspirin use for primary prevention of cardiovascular disease
por: Athena L. Huang, et al.
Publicado: (2024-06-01)

US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:
por: Athena L. Huang, MD, et al.
Publicado: (2023-09-01)

Preventing the progression of climate change: one drug or polypill?
por: Hugh Montgomery
Publicado: (2017-03-01)

Maybe it's time for something a little different? The extent to which current pharmacotherapy practice conforms to national guidelines for stroke and cardiovascular disease prevention
por: Sheppard, J, et al.
Publicado: (2013)

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
por: Price, H, et al.
Publicado: (2009)

Polypill holds promise for people with chronic disease
por: Jacqui Wise
Publicado: (2005-12-01)

Aspirin in the primary prevention of vascular disease Reply
por: Baigent, C, et al.
Publicado: (2009)